Publications by authors named "Kyle Udd"

Claim this Profile
B
Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New Therapy.
Sean Bujarski, Kyle Udd, Camilia Soof, Haiming Chen, Tanya M Spektor

Target Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma B-Cell Maturation Antigen Levels are Elevated and Correlate with Disease Activity in Patients with Chronic Lymphocytic Leukemia.
Kyle A Udd, Sean Bujarski, Eric Wirtschafter, Tanya M Spektor, Matthew Ghermezi

Target Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells.
Haiming Chen, Mingjie Li, Ning Xu, Nicole Ng, Eric Sanchez, Kyle Udd

Leuk Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study.
Zachary Gross, Ashkon Rahbari, Eric Wirtschafter, Tanya M Spektor, Kyle A Udd

Eur J Haematol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Monitoring multiple myeloma.
Kyle A Udd, Tanya M Spektor, James R Berenson

Clin Adv Hematol Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Aleksandra P Vidisheva, James Wang, Tanya M Spektor, Jacob D Bitran, Jose Lutzky, Kyle A Udd

Support Care Cancer· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects.
Haiming Chen, Mingjie Li, Eric Sanchez, Cathy S Wang, Tiffany Lee, Kyle A Udd

Mol Cancer Res· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.
Michael Ghermezi, Mingjie Li, Suzie Vardanyan, Nika Manik Harutyunyan, Jillian Gottlieb, Kyle Udd

Haematologica· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.
Ariana Berenson, Suzie Vardanyan, Michael David, James Wang, Nika Manik Harutyunyan, Kyle A Udd

Ann Hematol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib.
Ariana Berenson, Suzie Vardanyan, Michael David, James Wang, Nika Manik Harutyunyan, Kyle A Udd

Ann Hematol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of skin cancer in multiple myeloma patients: a retrospective cohort study.
Austin A Robinson, James Wang, Suzie Vardanyan, Erik K Madden, Frank Hebroni, Kyle A Udd

Eur J Haematol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.
James Wang, Kyle A Udd, Aleksandra Vidisheva, Regina A Swift, Tanya M Spektor

Support Care Cancer· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis